Transient cerebral ischaemic attacks--management and prognosis
- PMID: 7029501
- PMCID: PMC2424928
- DOI: 10.1136/pgmj.57.667.275
Transient cerebral ischaemic attacks--management and prognosis
Abstract
Fifty patients who had recently had a transient ischaemic attack took part in a double-blind cross-over trial of sulphinpyrazone 200 mg 4 times daily against placebo. Each treatment was given for 4 months. The incidence of recurrences was much greater in the initial 4 months but there was no difference between the 2 treatments. A follow-up of 39 of the patients showed that 2 years later 90% of those who had not had a recurrence during the 8 months had suffered no further neurological events whereas of those who did have a recurrence during the study only 47% had no further neurological events.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical